Sunflower Pharmaceutical to invest 50m yuan in R&D

Sunflower Pharmaceutical Group announced that its board of directors approved a resolution to invest up to 50 million yuan in product research and development. The decision, made via a telecommunication vote, received unanimous approval from all nine participating directors.

The approved R&D initiative aims to enrich the company's product portfolio and foster long-term growth. It includes the development of traditional Chinese medicine with identical names and formulas, research into chemical generic drugs to meet bioequivalence evaluation standards, and the expansion of indications for existing products. The board has authorized management to oversee the progress and specific details of these projects.

The board's decision falls within its purview and does not require a shareholder meeting for approval.